AceLink Therapeutics is a biopharmaceutical startup based in the San Francisco Bay Area, founded in 2019. The company's mission is to develop innovative drugs to combat genetically associated human diseases. Their initial focus is on creating a small molecule drug for polycystic kidney disease (PKD), a condition affecting 12 million patients globally. The recent Venture Round investment on 01 January 2022 attracted funding from Viva BioInnovator, Kaitai Capital, and Xiamen Changrong Investment Management. With a commitment to "overcome genetic diseases, one at a time," AceLink Therapeutics demonstrates potential in addressing unmet medical needs.
No recent news or press coverage available for AceLink Therapeutics.